Search Results for: "psoriasis"

Report will be subject to public deliberation at New England Comparative Effectiveness Public Advisory Council meeting on November 18th Boston, Mass., November 4, 2016 – The Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness and value of eight targeted immunomodulatory drugs for the treatment of plaque […]

September 29, 2016 – The Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the comparative clinical effectiveness and value of targeted immunomodulators for adults with moderate-to-severe plaque psoriasis. The report, as well as accompanying draft voting questions, will be open to public comment for three weeks. ICER is committed to engaging […]

Due to important feedback received from patient groups and other stakeholders regarding the time allotted for public comments, ICER is re-opening the public comment period for the Draft Scoping Document on treatments for non-small cell lung cancer. In addition, ICER is extending the currently ongoing public comment period on the Draft Scoping Document for a […]

–Document will inform development of report for public deliberation by the New England CEPAC– June 24, 2016- The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document that will inform a report on drug therapies for treatment of plaque psoriasis. The document will be open to public comment for one week, […]

-Dates for previously announced review of treatments for non-small cell lung cancer also posted- Boston, Mass., June 3, 2016 – The Institute for Clinical and Economic Review (ICER) will develop a report assessing the comparative clinical effectiveness and value of several existing and emerging therapies for the treatment of plaque psoriasis and psoriatic arthritis. The […]

— Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, white paper provides recommendations for appropriate design and implementation of policies that determine patient access to prescription drugs — — ICER has formed a multi-stakeholder Working Group to help guide assessment of major payer policies; by mid-2021, ICER will […]

In the United States, consequential decisions around prescription drug pricing and patient access are generally made based on limited evidence and without patients in the room.

By Steve Pearson(This commentary is being co-posted by The Donaghue Foundation)  In the United States, consequential decisions around prescription drug pricing and patient access are generally made based on limited evidence and without patients in the room. In confidential negotiations, drugmakers and insurers make financial tradeoffs that seriously affect the health and wealth of all Americans. […]

— Initial annual report to be issued in first quarter of 2019 — Boston – June 27, 2018 – The Institute for Clinical and Economic Review (ICER) today announced the formation of an advisory group to guide the development of a report on US drug price increases that are unsupported by clinical evidence. ICER plans to issue its […]

— The emerging drug may be cost-effective compared to no treatment if priced in line with analyst expectations, but large number of potentially eligible patients may pose short-term affordability challenges for health systems — BOSTON, June 15, 2018 – The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and […]